$USNU
Elite Health Systems Inc.

2022 Q1 Form 10-Q Financial Statement

#000114036122023991 Filed on June 24, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $1.061M
YoY Change -100.0% 42.03%
Cost Of Revenue $0.00 $86.00K
YoY Change -100.0% 8.86%
Gross Profit $0.00 $975.0K
YoY Change -100.0% 45.96%
Gross Profit Margin 91.89%
Selling, General & Admin $360.0K $298.0K
YoY Change 20.81% -1.32%
% of Gross Profit 30.56%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $360.0K $384.0K
YoY Change -6.25% 0.79%
Operating Profit -$360.0K $677.0K
YoY Change -153.18% 84.97%
Interest Expense $0.00 $2.000K
YoY Change -100.0% -81.82%
% of Operating Profit 0.3%
Other Income/Expense, Net -$133.0K -$133.0K
YoY Change 0.0%
Pretax Income -$493.0K $544.0K
YoY Change -190.63% 133.48%
Income Tax $2.000K $252.0K
% Of Pretax Income 46.32%
Net Earnings -$421.0K $292.0K
YoY Change -244.18% 66.86%
Net Earnings / Revenue 27.52%
Basic Earnings Per Share -$0.05 $0.04
Diluted Earnings Per Share -$0.05 $0.04
COMMON SHARES
Basic Shares Outstanding 7.792M 7.792M
Diluted Shares Outstanding 7.792M 7.792M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.658M $2.543M
YoY Change -34.8% 46.66%
Cash & Equivalents $1.658M $2.543M
Short-Term Investments
Other Short-Term Assets $47.00K $80.00K
YoY Change -41.25% -16.67%
Inventory
Prepaid Expenses
Receivables $828.0K
Other Receivables $0.00
Total Short-Term Assets $1.705M $3.451M
YoY Change -50.59% 0.61%
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K $86.00K
YoY Change -43.02% -28.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $146.0K $161.0K
YoY Change -9.32% -27.48%
Other Assets $965.0K $1.077M
YoY Change -10.4% -40.1%
Total Long-Term Assets $1.475M $1.163M
YoY Change 26.83% -39.36%
TOTAL ASSETS
Total Short-Term Assets $1.705M $3.451M
Total Long-Term Assets $1.475M $1.163M
Total Assets $3.180M $4.614M
YoY Change -31.08% -13.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $177.0K $166.0K
YoY Change 6.63% -38.06%
Accrued Expenses $44.00K $40.00K
YoY Change 10.0% 8.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $624.0K $322.0K
YoY Change 93.79% -83.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $23.00K $67.00K
YoY Change -65.67% -37.96%
Total Long-Term Liabilities $23.00K $67.00K
YoY Change -65.67% -37.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $624.0K $322.0K
Total Long-Term Liabilities $23.00K $67.00K
Total Liabilities $1.025M $389.0K
YoY Change 163.5% -80.74%
SHAREHOLDERS EQUITY
Retained Earnings $1.047M
YoY Change 598.0%
Common Stock $3.178M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.155M $4.225M
YoY Change
Total Liabilities & Shareholders Equity $3.180M $4.614M
YoY Change -31.08% -13.72%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$421.0K $292.0K
YoY Change -244.18% 66.86%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$336.0K $214.0K
YoY Change -257.01% -71.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$184.0K $388.0K
YoY Change -147.42% 2182.35%
Cash From Investing Activities -$184.0K $388.0K
YoY Change -147.42% 2182.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -89.00K
YoY Change -100.0% -75.95%
NET CHANGE
Cash From Operating Activities -336.0K 214.0K
Cash From Investing Activities -184.0K 388.0K
Cash From Financing Activities 0.000 -89.00K
Net Change In Cash -520.0K 513.0K
YoY Change -201.36% 28.57%
FREE CASH FLOW
Cash From Operating Activities -$336.0K $214.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7792185
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
0-15586
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5370333
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2400 Research Blvd, Suite 325
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2022Q1 dei City Area Code
CityAreaCode
301
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
208-8998
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1061000
CY2022Q1 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
0
CY2021Q1 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
86000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
360000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
298000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
360000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
384000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-360000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
677000
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
CY2021Q1 us-gaap Interest Expense
InterestExpense
2000
CY2022Q1 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
0
CY2021Q1 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
8000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-133000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-139000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-493000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
544000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-495000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
292000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-74000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-421000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
292000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7792185
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7792185
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7792185
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7792185
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-495000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
292000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8000
CY2022Q1 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-133000
CY2021Q1 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-139000
CY2022Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
11000
CY2021Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
0
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
482000
CY2022Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-11000
CY2021Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
252000
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-18000
CY2021Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-19000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4000
CY2022Q1 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
10000
CY2021Q1 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
10000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-336000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
214000
CY2022Q1 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
182000
CY2021Q1 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
144000
CY2022Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
2000
CY2021Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2022Q1 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
0
CY2021Q1 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
532000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
388000
CY2022Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
CY2021Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
89000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-89000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-520000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
513000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2178000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2030000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1658000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2543000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2022Q1 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252000

Files In Submission

Name View Source Status
0001140361-22-023991-index-headers.html Edgar Link pending
0001140361-22-023991-index.html Edgar Link pending
0001140361-22-023991.txt Edgar Link pending
0001140361-22-023991-xbrl.zip Edgar Link pending
brhc10037921_10q.htm Edgar Link pending
brhc10037921_10q_htm.xml Edgar Link completed
brhc10037921_ex31-1.htm Edgar Link pending
brhc10037921_ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20220331.xsd Edgar Link pending
usnu-20220331_cal.xml Edgar Link unprocessable
usnu-20220331_def.xml Edgar Link unprocessable
usnu-20220331_lab.xml Edgar Link unprocessable
usnu-20220331_pre.xml Edgar Link unprocessable